Latigo Biotherapeutics (LTGO) Stock Overview

Develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. More details

LTGO fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Risk Analysis

Makes less than USD$1m in revenue ($0)

Has less than 1 year of cash runway

Shares are highly illiquid

Less than 3 years of financial data is available

LTGO Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW486,100 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

486,100 investors already sharing narratives

View all narratives

Latigo Biotherapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Latigo Biotherapeutics
Historical stock prices
Current Share Price	US$18.52
52 Week High	US$22.47
52 Week Low	US$17.22
Beta	0
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	1.48%

Recent updates

Shareholder Returns

	LTGO	US Pharmaceuticals	US Market
7D	n/a	4.3%	0.09%
1Y	n/a	58.8%	19.0%

Return vs Industry: Insufficient data to determine how LTGO performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how LTGO performed against the US Market.

Price Volatility

Is LTGO's price volatile compared to industry and market?
LTGO volatility
LTGO Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	9.1%
Market Average Movement	7.2%
10% most volatile stocks in US Market	16.3%
10% least volatile stocks in US Market	3.1%

Stable Share Price: LTGO's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine LTGO's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2018	59	Nima Farzan	latigobio.com

Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. The company's pipeline includes LTG-001, an oral NaV1.8 inhibitor designed to provide fast-acting, opioid-sparing relief for the treatment of acute pain; LTG-321, a NaV1.8 inhibitor candidate developed for the treatment of chronic musculoskeletal pain, starting with osteoarthritis; and LTG-418, a NaV1.8 inhibitor developed for the treatment of acute and chronic pain. Latigo Biotherapeutics, Inc. was formerly known as WVB-Desmond, Inc. and changed its name to Latigo Biotherapeutics, Inc. in March 2019.

Latigo Biotherapeutics, Inc. Fundamentals Summary

How do Latigo Biotherapeutics's earnings and revenue compare to its market cap?
LTGO fundamental statistics
Market cap	US$1.17b
Earnings (TTM)	-US$111.18m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-10.5x

P/E Ratio

Is LTGO overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
LTGO income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$111.18m
Earnings	-US$111.18m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)	-1.76
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did LTGO perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/08/11 16:11
End of Day Share Price	2026/08/11 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Latigo Biotherapeutics, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Latigo Biotherapeutics, Inc.NasdaqGS:LTGO Stock Report